Allogene CAR-Ts’ Durability Remains A Question, But Strong Data So Far

Pivotal Trial Likely To Include Consolidation Dosing

Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.

Digital illustration of Cancer cell in colour background
Allogene announced data for its off-the-shelf CAR-Ts in non-Hodgkin's lymphoma • Source: Shutterstock

Allogene Therapeutics Inc.’s interim Phase I data for its allogeneic chimeric antigen receptor T-cell (CAR-T) therapies, ALLO-501 and ALLO-501A, look increasingly comparable to marketed autologous CAR-Ts in terms of response rates among patients with B-cell non-Hodgkin’s lymphomas, particularly with their added advantage of enabling consolidation treatment. But while those responses look durable so far, a lingering question is whether that durability will continue long enough to approach or match the durable responses seen with their autologous cousins.

South San Francisco, CA-based Allogene announced 19 May data from the ALPHA study of ALLO-501 and the ALPHA2 study of ALLO-501A, both of which target CD19 and are being tested in patients with follicular lymphoma (FL) and large B-cell lymphoma (LBCL)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ASCO

More from Conferences